About Kawin

POSITION:Home>News

KW-136 in Combination with Sofosbuvir Under Phase 3 Trial

Date:2017-05-31 12:29Source:Kawin TechnologyWriter:Kawin Technology

In May 2017, Kawin Technology initiated a phase 3 trial program to investigate use of KW-136, an investigational DAA against HCV, in combination with sofosbuvir for treatment of pan-genotypic HCV infection. This regimen is expected to provide the first-in-China, all-oral, pan-genotypic treatment for HCV- infected patients, including those with cirrhosis.